Company news

ANI Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

August 8, 2023

ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8: 30 a.m. ET

July 30, 2023

ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 21, 2023

ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 15, 2023

ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity

May 14, 2023

ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock

May 11, 2023

ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock

May 10, 2023

ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

May 7, 2023

ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8: 30 a.m. ET

April 26, 2023

ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 25, 2023

ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP

April 23, 2023

ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP

April 3, 2023

ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance

March 8, 2023

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8: 30 a.m. ET

February 21, 2023

ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP

December 18, 2022

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

November 27, 2022

ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP

November 15, 2022

ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues

November 8, 2022

ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8: 00 a.m. ET

October 23, 2022

ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

September 11, 2022

ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

August 28, 2022

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

August 15, 2022

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel

August 7, 2022

ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

August 2, 2022

ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC

July 27, 2022

ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8: 00 a.m. ET

July 24, 2022

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

July 17, 2022

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP

June 21, 2022

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

June 20, 2022

ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition

June 1, 2022

ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

May 31, 2022

ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences

May 19, 2022

ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million

May 9, 2022

ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022

April 18, 2022

ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets

April 10, 2022

ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors

March 21, 2022

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth

March 14, 2022

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

March 6, 2022

ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team

February 23, 2022

Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity

February 13, 2022

ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders

January 23, 2022

ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference

January 2, 2022

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP

December 20, 2021

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

December 19, 2021

ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021

November 21, 2021

ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses

November 21, 2021

ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma

November 10, 2021

ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock

November 7, 2021

ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

November 2, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 58 decks. Every deck is listed under its year.